Logo image of BDRX

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Price, Quote, News and Overview

NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD

1.43  -0.03 (-2.05%)

After market: 1.47 +0.04 (+2.8%)

BDRX Quote, Performance and Key Statistics

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (4/17/2025, 8:03:39 PM)

After market: 1.47 +0.04 (+2.8%)

1.43

-0.03 (-2.05%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High74
52 Week Low1.14
Market Cap3.66M
Shares2.56M
Float2.50M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-08 2014-12-08


BDRX short term performance overview.The bars show the price performance of BDRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

BDRX long term performance overview.The bars show the price performance of BDRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BDRX is 1.43 USD. In the past month the price decreased by -28.5%. In the past year, price decreased by -92.39%.

BIODEXA PHARMACEUTICALS-ADR / BDRX Daily stock chart

BDRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 320.54 36.40B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.89B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About BDRX

Company Profile

BDRX logo image Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 21 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Company Info

BIODEXA PHARMACEUTICALS-ADR

1 Caspian Point, Caspian Way

Abingdon OXFORDSHIRE GB

Employees: 21

Company Website: https://www.biodexapharma.com/

Investor Relations: http://biodexapharma.com/investors/

Phone: 4401235888300

BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ

What is the stock price of BIODEXA PHARMACEUTICALS-ADR today?

The current stock price of BDRX is 1.43 USD. The price decreased by -2.05% in the last trading session.


What is the ticker symbol for BIODEXA PHARMACEUTICALS-ADR stock?

The exchange symbol of BIODEXA PHARMACEUTICALS-ADR is BDRX and it is listed on the Nasdaq exchange.


On which exchange is BDRX stock listed?

BDRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIODEXA PHARMACEUTICALS-ADR stock?

7 analysts have analysed BDRX and the average price target is 204 USD. This implies a price increase of 14165.73% is expected in the next year compared to the current price of 1.43. Check the BIODEXA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIODEXA PHARMACEUTICALS-ADR worth?

BIODEXA PHARMACEUTICALS-ADR (BDRX) has a market capitalization of 3.66M USD. This makes BDRX a Nano Cap stock.


How many employees does BIODEXA PHARMACEUTICALS-ADR have?

BIODEXA PHARMACEUTICALS-ADR (BDRX) currently has 21 employees.


What are the support and resistance levels for BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?

BIODEXA PHARMACEUTICALS-ADR (BDRX) has a resistance level at 1.44. Check the full technical report for a detailed analysis of BDRX support and resistance levels.


Is BIODEXA PHARMACEUTICALS-ADR (BDRX) expected to grow?

The Revenue of BIODEXA PHARMACEUTICALS-ADR (BDRX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BDRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIODEXA PHARMACEUTICALS-ADR (BDRX) stock pay dividends?

BDRX does not pay a dividend.


What is the Price/Earnings (PE) ratio of BIODEXA PHARMACEUTICALS-ADR (BDRX)?

BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.5).


What is the Short Interest ratio of BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?

The outstanding short interest for BIODEXA PHARMACEUTICALS-ADR (BDRX) is 5.93% of its float. Check the ownership tab for more information on the BDRX short interest.


BDRX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BDRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BDRX. Both the profitability and financial health of BDRX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BDRX Financial Highlights

Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -20.5. The EPS increased by 98.74% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.82%
ROE -78.14%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%97.22%
Sales Q2Q%-100%
EPS 1Y (TTM)98.74%
Revenue 1Y (TTM)-84.31%

BDRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to BDRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 80.32% and a revenue growth -100% for BDRX


Ownership
Inst Owners29.86%
Ins Owners3.64%
Short Float %5.93%
Short Ratio0.03
Analysts
Analysts85.71
Price Target204 (14165.73%)
EPS Next Y80.32%
Revenue Next Year-100%